Full-Time

Director – Product Management

Telehealth

Posted on 7/19/2023

23andMe

23andMe

501-1,000 employees

Direct-to-consumer DNA testing services

Compensation Overview

$240k - $360k/yr

Expert

Sunnyvale, CA, USA

Requires onsite presence in Sunnyvale, California for a minimum of three days per week.

Requires onsite presence in Sunnyvale, California for a minimum of three days per week.

Requires onsite presence in Sunnyvale, California for a minimum of three days per week.

Category
Product Management
Product
Required Skills
Communications
Requirements
  • 10+ years of experience in product management at a technology company for a consumer-facing product, ideally in the healthtech / telehealth space
  • 5+ years experience hiring, mentoring, and leading a team of product managers
  • Deep experience with cash-pay telepharmacy and telehealth
  • 4+ years of experience developing features or functionality requiring a high level of user-centric design and iteration
  • Strong analytical skills, including a command of A/B testing
  • Exemplary communication, presentation, and organizational skills
  • Experience in highly regulated industries navigating delivering customer value in the midst of requirements and approvals required by regulations
  • Innovative thinking and problem solving
  • Independent and proactive leadership
  • Ability to work from 23andMe's office in Sunnyvale, CA a minimum of 3 days per week
Responsibilities
  • Drive a pipeline of product features and enhancements for personalized care based on genetics and health factors
  • Identify customer pain points and opportunities, build business cases, and brainstorm product opportunities
  • Communicate priorities, requirements, plans, and project status with key stakeholders
  • Collaborate with Engineering and Design to plan, build, and launch features
  • Partner with various teams to operationalize new initiatives and create high-value patient experiences
  • Define success metrics, measure, and evaluate the impact of product efforts
  • Maximize efficiency in a constantly evolving environment

23andMe offers direct-to-consumer DNA testing that provides individuals with insights into their ancestry, genetic traits, and potential health risks. Customers purchase a DNA testing kit, send in a saliva sample, and receive personalized genetic reports based on the analysis of their DNA. This service appeals to a wide range of people, from those curious about their family history to those wanting to understand their health predispositions. Unlike many competitors, 23andMe not only sells these kits but also offers subscription services for ongoing updates and insights based on new genetic research. Additionally, the company utilizes its large genetic database for research collaborations, which can lead to further revenue through partnerships with research institutions and pharmaceutical companies. The goal of 23andMe is to empower individuals with knowledge about their genetics while contributing to advancements in genetic research.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

2006

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in personalized medicine boosts demand for genetic testing services.
  • Advancements in AI improve the accuracy of genetic data analysis and consumer insights.
  • Collaborations with pharmaceutical firms accelerate drug discovery using genetic data.

What critics are saying

  • Regeneron's acquisition may alter 23andMe's business strategy, affecting customer services.
  • Bankruptcy proceedings could disrupt operations and create uncertainty for employees and customers.
  • Intensifying competition in consumer genetics may impact 23andMe's market share.

What makes 23andMe unique

  • 23andMe offers direct-to-consumer DNA testing, a pioneering service in genetics.
  • The company provides personalized genetic reports, enhancing consumer understanding of health risks.
  • 23andMe collaborates with research institutions, leveraging its genetic database for scientific advancements.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health, vision, & dental plans

Family planning, support, & leave for parents

Mental healthcare

Student loan assistance

Volunteer time off

Dog friendly office

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

2%

2 year growth

0%
Glass Railing
Jun 18th, 2025
23andMe's African American Community Update: A Genetic Revolution for African American Heritage

23andMe, a leader in genetic testing, has recently announced an update to its African American Community feature, a move that has been hailed as a significant step forward in genetic research and heritage exploration.

GlobeNewswire
Jun 13th, 2025
23Andme Reaches Agreement For Sale Of Business To Ttam Research Institute Following Final Round Of Bidding In Court-Approved Sale Process

TTAM Commits to Comply with Company’s Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement with TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and led by 23andMe Co-Founder and former CEO Anne Wojcicki, for the sale of substantially all of the Company’s assets, including the Personal Genome Service (PGS) and Research Services business lines and the Lemonaid Health business, for a purchase price of $305 million. The agreement with TTAM is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ: REGN). The final round of bidding was conducted according to procedures approved by the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court") and designed to allow the Special Committee of 23andMe’s Board of Directors to obtain, consistent with its fiduciary duties, the most value-maximizing transaction for the Company’s stakeholders

Kaufman Hall
Jun 13th, 2025
Gist Weekly: June 13, 2025

Regeneron Pharmaceuticals is seeking to buy 23andMe and said it would honor all existing consents, privacy policies and statements, terms of services and notices.

Startup Hub
Jun 5th, 2025
23andMe Raises $305M in Funding

23andMe has secured a new funding round of $305 million, led by its former CEO. The investment aims to advance the company's mission of empowering individuals with genetic information, likely supporting research, service expansion, and growth in personal genomics. The article highlights investor confidence in 23andMe's approach but lacks details on the investment round type and other investors.

Perplexity AI
Jun 4th, 2025
23andMe seeks new bids after co-founder offers $305 million

Bankrupt genetic testing company 23andMe is seeking new bids following a $305 million offer from co-founder Anne Wojcicki, who has secured backing from an...

INACTIVE